Skip to content
Markets News
Earnings1 min read

Sun Pharma Profit Drops 36% as Litigation and Deal Costs Bite

Makkler Newsroom
October 30, 2026 · Based on reporting by The Economic Times

Quarterly revenue rose 12%, while exceptional charges tied to US litigation and the proposed Organon acquisition weighed on reported earnings.

Key takeaways

  • Net profit fell 36% year over year to Rs 1,989 crore.
  • Revenue from operations increased 12% to Rs 16,199 crore.
  • Exceptional charges totaled Rs 1,269 crore, largely tied to US litigation and Organon acquisition costs.

Sun Pharmaceutical Industries reported a 36% year-on-year decline in consolidated net profit to Rs 1,989 crore for the September quarter. Revenue from operations rose 12% to Rs 16,199 crore.

The company recognized Rs 1,269 crore in exceptional charges, largely related to a US generic-drug pricing litigation settlement and costs for its proposed Organon acquisition. Excluding exceptional items, net profit increased 1% to Rs 3,162 crore.

EBITDA rose 5% to Rs 4,744 crore, while the EBITDA margin narrowed to 29.3% from 31.3% a year earlier. Domestic formulations sales increased 17% to Rs 5,552 crore, and the company launched 14 products in India during the quarter.

US formulations sales fell 8.2% to $455 million, mainly because of lower lenalidomide sales, the company said. Excluding that drug, US sales increased marginally. Global innovative medicines sales rose 6.9% to $356 million.

As of 9:58 UTC on Friday, Sun Pharma shares traded at Rs 1,777.70, up 0.95% since the previous close.

Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.